The first step is to understand the testing landscape and key contributing leakage sources across key regions. Maintain coordination and alignment. There is evidence that some pharma companies are improving their CDx commercialization through a range of approaches, including partnering to develop new tests, staffing organizations with diagnostics specialists, working more closely with CDx partners on commercialization, and forging commercial partnerships with laboratories and other stakeholders.
However, commercializing CDx products remains a challenge for pharmaceutical companies as it may require touching unfamiliar stakeholders and processes as well as performing a range of incremental activities.
Build the team. While this represents a step in the right direction, test leakage remains a significant issue that pharma needs to address; handled correctly, these approaches could in the long run significantly improve pharma commercialization models. As the era of blockbuster drugs aimed at a large market diminishes, the era of personalized medicine is just beginning.
December 12th, 2018 Payer Research.
Healthcare professionals seek assistance in these areas:. This case study illustrates the evolution of the diagnostic industry across different continents, diagnostic companies' evolving business models, stak... A framework that that captures potential leakage sources along the test journey from drug consideration and test ordering through the reporting of an actionable test result can facilitate the identification of leakage sources.
Understand leakage and root cases.
An Inside Look at Diagnostics. Every test and situation is unique, and barriers faced may evolve over the lifecycle.The role of Companion Diagnostics for the Pharma Industry #ASCO17
Look for all our new branding soon! Here are starting guidelines for companies to follow:.
Similarly, companies need to ensure that internal stakeholders remain fully and actively aligned. Traditionally, however, many in pharma have not aligned strategically with their CDx commercialization partners early on, defined remit for the internal therapeutics brand team and the CDx partner team, or installed coordinated performance metrics and incentives.
BRAF mutation testing in melanoma: In 2015, the Tufts Center for the Study of Drug Development estimated that 73 percent of cancer drugs, and 42 percent of all drugs, in development are paired with a diagnostic test to identify patients who can benefit from them.
Further, pharma and their CDx partners may not always be aware of the technological, regulatory, and educational requirements needed to commercialize products with companion diagnostics, nor are they always resourced and incentivized to address those requirements effectively.
Get the latest articles from Pharmaceutical Online delivered to your inbox. While this represents a step in the right direction, test leakage remains a significant issue that pharma needs to address; handled correctly, these approaches could in the long run significantly improve pharma commercialization models. In 2015, the Tufts Center for the Study of Drug Development estimated that 73 percent of cancer drugs, and 42 percent of all drugs, in development are paired with a diagnostic test to identify patients who can benefit from them.
Review our Cookies Policy for more information.